Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte C Widemann

Showing results (121-130 of 203) with videos related to

Pageof 21
Sort By:
Pediatric Blood & Cancer|September 27, 2014
Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I ConsortiumStephan D Voss, Julia Glade-Bender, Sheri L Spunt, et al.
Journal of Cancer Research and Clinical Oncology|May 3, 2024
Germline findings in cancer predisposing genes from a small cohort of chordoma patientsMargarita Raygada, Liny John, Anne Liu, et al.
Clinical Trials (London, England)|June 3, 2023
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trialsAshley Cannon, Kavita Y Sarin, Andrea K Petersen, et al.
Neuro-Oncology|October 16, 2014
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Brigitte C Widemann, Pamela Wolters, et al.
Endocrine-Related Cancer|December 11, 2025
The Prostate is a Common Site of Disease in Patients with MEN2B and Medullary Thyroid CarcinomaIra L Kraft, Srivandana Akshintala, Andrea Gross, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
A molecular basis for neurofibroma-associated skeletal manifestations in NF1Yun Ma, Andrea M Gross, Eva Dombi, et al.
Molecular Cancer Therapeutics|February 4, 2021
Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical BiopsiesWilliam G Herrick, Casey L Kilpatrick, Melinda G Hollingshead, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsElizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
JCO Clinical Cancer Informatics|April 8, 2026
Childhood Cancer Data Initiative Participant Index: Mapping Pediatric Cancer Data to Facilitate Cross-Study Integrated AnalysisSubhashini Jagu, Jaime M Guidry Auvil, Mark D Cunningham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2023
MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath TumorsDana C Borcherding, Neha V Amin, Kevin He, et al.
Pageof 21

Showing results (121-130 of 203) with videos related to

Sort By:
Pageof 21
Pediatric Blood & Cancer|September 27, 2014
Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I ConsortiumStephan D Voss, Julia Glade-Bender, Sheri L Spunt, et al.
Journal of Cancer Research and Clinical Oncology|May 3, 2024
Germline findings in cancer predisposing genes from a small cohort of chordoma patientsMargarita Raygada, Liny John, Anne Liu, et al.
Clinical Trials (London, England)|June 3, 2023
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trialsAshley Cannon, Kavita Y Sarin, Andrea K Petersen, et al.
Neuro-Oncology|October 16, 2014
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II studyBrian Weiss, Brigitte C Widemann, Pamela Wolters, et al.
Endocrine-Related Cancer|December 11, 2025
The Prostate is a Common Site of Disease in Patients with MEN2B and Medullary Thyroid CarcinomaIra L Kraft, Srivandana Akshintala, Andrea Gross, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
A molecular basis for neurofibroma-associated skeletal manifestations in NF1Yun Ma, Andrea M Gross, Eva Dombi, et al.
Molecular Cancer Therapeutics|February 4, 2021
Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical BiopsiesWilliam G Herrick, Casey L Kilpatrick, Melinda G Hollingshead, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsElizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
JCO Clinical Cancer Informatics|April 8, 2026
Childhood Cancer Data Initiative Participant Index: Mapping Pediatric Cancer Data to Facilitate Cross-Study Integrated AnalysisSubhashini Jagu, Jaime M Guidry Auvil, Mark D Cunningham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2023
MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath TumorsDana C Borcherding, Neha V Amin, Kevin He, et al.
Pageof 21